A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Megan Durham
The Oncologist
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Esmo Open
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
Esmo Open
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Journal of Hematology and Oncology
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Therapeutics Advances in Medical Oncology
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
Breast Cancer Research
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Journal of Clinical Oncology
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Journal of Clinical Oncology
Nature Medicine
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results